Article
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.
Medical oncology (Northwood, London, England) - 15 May 2022
Voutsadakis Ioannis A
Abstract excerpt
Colorectal cancer remains a major cause of cancer-related morbidity and mortality. Metastatic disease is still incurable in most cases. New therapies based on a better understanding of the pathogenesis are needed to improve outcomes. Mutations in the catalytic sub-unit of kinase PI3K encoded by gene PIK3CA are common in colorectal cancer cell lines and patient samples. The characteristics of colorectal cancer...
Topics
- Cell Line
- Class I Phosphatidylinositol 3-Kinases
- Colorectal Neoplasms
- Drug Discovery
- Humans
- Microsatellite Instability
- Mutation
- Phosphatidylinositol 3-Kinases
- Phosphoinositide-3 Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Proto-Oncogene Proteins p21(ras)